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The peptide hormone hepcidin is a key homeostatic
regulator of iron metabolism and involved in patho-
logical regulation of iron in response to infection,
inflammation, hypoxia, and anemia. It acts by binding
to the iron exporter ferroportin, causing it to be inter-
nalized and degraded; however, little is known about
the structure/activity relationships of the interaction
of hepcidin with ferroportin. We show that there are
key residues in the N-terminal region of hepcidin
that influence its interaction with ferroportin, and
we explore the structure/function relationships at
these positions. A series of hepcidin mutants in
which disulfide bonds were replaced with diselenide
bonds showed no change in activity compared to
native hepcidin. These results identify important
constraints for the development of hepcidin conge-
ners for the treatment of hereditary iron overload.
INTRODUCTION
The peptide hormone hepcidin is a key regulator of iron homeo-
stasis and is produced by the liver in response to high plasma
iron levels and inflammatory stimuli (Ganz, 2008; Nemeth and
Ganz, 2006). Ferroportin is the sole cellular iron exporter and is
expressed on the surface of intestinal enterocytes, macro-
phages, hepatocytes, and placenta where it releases cellular
iron into the plasma (Donovan, et al., 2005). Hepcidin acts by
binding to ferroportin, causing the transporter to be internalized
and degraded (Nemeth, et al., 2004). The rate of iron efflux from
these cells is proportional to the level of ferroportin on the cell
membranes. Therefore, hepcidin-induced degradation of ferro-
portin results in a decrease in the circulating levels of iron within
the body.
Hepcidin is synthesized as an 84 amino acid prepropeptide
that is subsequently processed to themature 25 residue peptide,
which contains eight cysteines, linked to form four disulfide
bonds (Figure 1) (Krause, et al., 2000; Park, et al., 2001). The
connectivity of these disulfide bonds was originally proposed,
based on a detailed NMR analysis, to be in a Cys7 to Cys23,
Cys10 to Cys22, Cys11 to Cys19, and Cys13 to Cys14 ladder-
like arrangement that includes a rare vicinal disulfide bond
(between Cys 13 and 14) (Hunter, et al., 2002). A later structural
study on bass hepcidin reported the same disulfide connectivity336 Chemistry & Biology 18, 336–343, March 25, 2011 ª2011 Elsevie(Lauth, et al., 2005). However, recently it has been shown,
using NMR, disulfide mapping, and X-ray crystallography, that
this connectivity is apparently incorrect and that, instead, the
disulfides form a different connectivity that shares two of the
disulfides from the originally proposed connectivity, Cys7 to
Cys23 and Cys11 to Cys19, but the vicinal disulfide is absent,
and the other two disulfide bonds are located between Cys10
and Cys13 and Cys14 and Cys22 (Jordan, et al., 2009). In this
structure hepcidin forms a b-hairpin-like motif containing
a central core crosslinked by disulfides and a flexible six residue
N-terminal region. It was shown that at physiological tempera-
ture, hepcidin interconverts between two conformations
(Jordan, et al., 2009). NMR studies at lower and higher temper-
atures showed that the conformational variation occurs predom-
inantly around the b-hairpin region of the peptide and that the
N-terminal region is flexible at all temperatures. The physiolog-
ical role, if any, of this conformational flexibility remains unclear.
Hepcidin is deactivated by cleavage of the N-terminal region
of the molecule, as indicated by the presence of a 20 residue
inactive form of hepcidin isolated from urine (Park, et al., 2001).
The N-terminal region of hepcidin is essential for binding to
ferroportin because sequential truncation of the N-terminal
residues results in a progressive loss in activity of the peptide,
yet the N-terminal region alone is not sufficient to induce ferro-
portin internalization (Nemeth, et al., 2006). In addition it has
been shown that Cys326 of ferroportin is required for the interac-
tion between hepcidin and ferroportin, which raises the possi-
bility that, among other explanations, a disulfide bond might
form between hepcidin and ferroportin (Fernandes, et al., 2009).
Hepcidin dysregulation results in a number of disease states.
Hemochromatosis is a genetic condition characterized by
abnormally high levels of circulating iron, resulting in iron depo-
sition and subsequent organ damage (Alexander and Kowdley,
2009). Most forms of hemochromatosis result from a deficiency
in hepcidin production, and therefore, it should be possible to
treat hemochromatosis by administration of synthetic hepcidin
or a hepcidin analog. At the other extreme, in anemia of chronic
disease associated with chronic infection or inflammation, high
hepcidin levels limit the availability of iron for hemoglobin
synthesis. Here, antagonists of hepcidinmight be therapeutically
useful in correcting the iron imbalance.
A key element in the potential development of hepcidin-based
treatments for iron regulatory disorders is an understanding of
the structure/activity relationships of hepcidin and its interaction
with ferroportin. In this study we undertakemutational studies on
the N-terminal residues of hepcidin to elucidate these relation-
ships. As our initial approach we performed an alanine scan tor Ltd All rights reserved
Figure 1. Sequences and Three-Dimensional Structure of Hepcidin
(A) Sequence alignment of selected hepcidin sequences illustrating the high
sequence conservation and the N-terminal region essential for biological
activity. The sequences contain eight conserved cysteines that form four disul-
fide bonds, indicated by the lines above the sequence list.
(B) A ribbon depiction of the three-dimensional structure of hepcidin showing
the b sheet structure (broad arrows) and the four disulfide bonds (ball and
sticks).
Figure 2. Oxidation and Purification of the Hepcidin Analogs
Oxidation of the reduced hepcidin analogs results in a complex mixture of
disulfide isomers, but typically with one predominant species (top). This major
isomer for each analog was successfully purified by RP-HPLC (bottom)
for structural analysis by NMR and bioactivity assays. The example shown is
for the I6K mutant.
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Structure/Function Studies on Hepcidindetermine the specific residues within the N terminus of hepcidin
that are involved in its interaction with ferroportin. We subse-
quently explored the important structural and chemical features
required at each of the key positions identified from the alanine
scan to establish the structure/activity profile of the critical
N terminus of hepcidin. A series of selenocysteine mutants
were also examined in an attempt to determine the role of disul-
fide exchange in the hepcidin/ferroportin interaction. These
studies have provided a mechanistic insight into the binding
mode of hepcidin with ferroportin.RESULTS
Peptide Synthesis
The synthesis of the hepcidin analogs for the structure/activity
studies was undertaken in two rounds. The first round involved
the synthesis of a series of alaninemutants in which each residue
of the N-terminal region was individually replaced with alanine.
The second round of analogs was based on bioactivity data
(described below) and involved mutations of residues His3,
Phe4, and Ile6. All analogs were successfully synthesized via
solid-phase synthesis methods utilizing Fmoc chemistry. After
assembly and cleavage from the resin using TFA, the peptides
were oxidized in phosphate buffer containing guanidine, EDTA,Chemistry & Biology 18, 3cysteine, and cystine to yield a complex mixture of disulfide
isomers, as illustrated by the RP-HPLC trace of the crude oxida-
tion mixture shown in Figure 2. Despite this complexity, we were
able to isolate, in high purity, a major isomer for 24 of the 26
analogs synthesized (Figure 2). Each of these isomers was
analyzed by NMR spectroscopy to confirm that they possessed
the native hepcidin fold. Two of the analogs synthesized, F9K
and G20F, could not be successfully oxidized to a native-like
molecule. These two mutations were originally chosen because
of the high sequence conservation at these positions and their
proximity to the N-terminal region, and therefore, we believed
that they might play a role in the biological activity of hepcidin.
However, our results suggest that Phe9 and Gly20 might be
conserved because they are important for the correct folding
of hepcidin.
Six selenocysteine analogs of hepcidin were designed, i.e.,
[C7U,C23U]hepcidin, [C10U,C13U]hepcidin, [C11U,C19U]hep-
cidin, [C14U,C22U]hepcidin, [C7U,C10U,C13U,C23U]hepcidin
(Sec4), and [C7U,C10U,C11U,C13U,C14U, C19U,C22U,C23U]
hepcidin (Sec8), with the aim of elucidating the role of one or
more of the disulfide bonds of hepcidin in a potential disulfide
exchange with ferroportin. Due to the low pKa and highly nega-
tive redox potential of selenocysteine, the formation of a disele-
nide bond is favored over a mixed selenylsulfide; furthermore,
diselenides are highly resistant to reduction by thiols (Armishaw,
et al., 2006; Muttenthaler and Alewood, 2008). Therefore, if one
of the hepcidin disulfide bonds underwent exchange with ferro-
portin, replacing it with a diselenide would result in a loss of
activity because it would be unlikely to form a selenylsulfide36–343, March 25, 2011 ª2011 Elsevier Ltd All rights reserved 337
Figure 3. NMR Secondary Shift Analysis of the Alanine Mutants of
Hepcidin
All alanine mutants had almost identical aH secondary shift values to native
hepcidin except for very small local changes around the site of substitution.
A similar trend was observed for all the other hepcidin mutants analyzed in
this study (Figure S1).
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Structure/Function Studies on Hepcidinbond with the free thiol of the ferroportin Cys326 residue. The
selenocysteine analogs of hepcidin were synthesized by solid-
phase peptide synthesis using BOC chemistry. The peptides
were cleaved from the resin using hydrofluoric acid and during
this process generated peptide in which the selenocysteines
were oxidized as expected (Muttenthaler and Alewood, 2008).
The remaining cysteines were then oxidized under the same
conditions used for the structure/activity analogs. Interestingly,
the [Sec8]hepcidin analog, in which all the cysteines are replaced
with selenocysteine, folded into a single major oxidized product
in hydrofluoric acid during the resin cleavage reaction that was
subsequently shown by NMR to be the native isomer. The
peptides were then purified by RP-HPLC and analyzed by
NMR to confirm that they were correctly folded.
NMR Studies
NMR spectroscopy was used to confirm that the hepcidin
analogs all possessed a native fold. NHi-NHi+1, aHi-NHi+1, and
bHi-NHi+1 connectivities obtained from the NOESY spectrum
for each analog were used in the sequential assignment of
individual spin systems determined from the TOCSY spectrum.
Sequential aHi-NHi+1 connectivities were seen for the entire
peptide chain except for residues 14–15, which were not visible
in the spectra, and at Pro5. The absence of residues Cys14 and
His15 is consistent with a similar observation for the native
peptide (Hunter, et al., 2002; Jordan, et al., 2009). The presence
of aHi-dHi+1 NOE correlations indicated that Pro5 was in a trans
configuration in all analogs.
Secondary aH chemical shifts are the difference between an
observed aH chemical shift and that of the corresponding
residue in a random coil peptide. A comparison of secondary
aH shifts between different peptides provides information on
the similarity of their structures. Furthermore, an analysis of
secondary shift data yields information on the secondary struc-
tures present within peptides. Figure 3 shows a comparison
between the secondary aH chemical shifts of the six alanine
mutants and native hepcidin and highlights the structural simi-
larity between these peptides. Only small local variations in
secondary shifts are observed in the N-terminal region around
the sites of amino acid substitution in each analog. The trends
in shifts for the core of the molecule, which is defined by the
cystine framework, are almost identical, including a series of
positive secondary shift values from residues 6 to 11 and 17 to
24, consistent with the proposed b-hairpin structure of hepcidin.
Similar results were observed for the structural analysis of the
position 3, 4, and 6 analogs and the selenocystine analogs
(see Figure S1 available online). Therefore, any changes in
biological activity observed are likely to be due to changes in
the chemical characteristics of the specific amino acids and
not a change in the global structure of the peptides.
Bioactivity of the Hepcidin Analogs
The ability of the hepcidin analogs to induce ferroportin internal-
ization and degradation was assessed by a measurement of the
suppression of fluorescence in HEK cells expressing ferroportin-
GFP. Peptides (0.3 mM) were added to the cells, and the activity
of each mutant was expressed as a percentage of native hepci-
din activity (Table 1). The initial screening was performed on the
alanine mutants to characterize the effect of mutation of each338 Chemistry & Biology 18, 336–343, March 25, 2011 ª2011 Elsevieindividual amino acid of the N terminus on activity of the peptide
(Figure 4A). Mutation of residues Thr2 to alanine resulted in no
significant change in activity compared with native hepcidin,
with suppression of fluorescence relative to hepcidin of 88% ±
13%. A moderate loss in activity was observed on mutation of
Asp1 (68% ± 5%) and Pro5 (77% ± 3%) to alanine. The largest
effect was seenwhenHis3, Phe4, or Ile6 was changed to alanine,
with these mutants having only 49% ± 1%, 33% ± 18%, and
31%± 4%, respectively, of the activity of native hepcidin. There-
fore, the key residues identified by the alanine scan for the inter-
action between hepcidin and ferroportin are His3, Phe4, and Ile6.
A second series of analogs was then made to elucidate the
specific chemical requirements at each of these positions
required for binding of hepcidin to ferroportin (Figures 4B–4D).
None of the three positions tolerated the presence of positively
or negatively charged residues because substitution of lysine
or aspartic acid at any of these positions resulted in almost
complete loss in activity. At position 3 (Figure 4B), substitution
of the histidine with a phenylalanine ring resulted in an almost
fully active peptide (92% ± 0.3%), suggesting that the nitrogens
in the histidine ring are not required for interaction with the
receptor. A tryptophan at position 3 resulted in a substantial
loss of activity (56% ± 5%), presumably due to the greater bulk
of this residue. Changing the stereochemistry by incorporation
of a D-histidine resulted in some loss in activity (73% ± 2%),
which suggests that although the side chain orientation of this
residue has some effect, either ferroportin can accommodate
this change to some degree, or the flexibility of the N terminus
can compensate for the change in stereochemistry. Replace-
ment of Phe4 with a cyclohexylalanine or a norleucine resulted
in little or no loss in activity (88%± 8%and 105%±11%, respec-
tively), indicating that neither an aromatic or ring moiety is
required at this position and that a long hydrophobic side chainr Ltd All rights reserved




Hepcidin ± SEM (%)a
Hepcidin 100
D1A 67 ± 5
T2A 88 ± 13
H3A 49 ± 1
F4A 33 ± 18
P5A 77 ± 3
I6A 31 ± 4
H3F 92 ± 0.3
H3W 56 ± 5
H3h 73 ± 2
H3Dab 14 ± 0.1
H3K 9 ± 2
H3D 7 ± 6
F4Cha 88 ± 8
F4Nle 105 ± 11
F4Y 75 ± 22
F4f 29 ± 15
F4K 15 ± 15
F4D 12 ± 10
I6F 64 ± 4
I6i 55 ± 2
I6K 18 ± 12
I6D 2 ± 5
I8K 87 ± 5
P5O 89 ± 2
Activity relative to native hepcidin using the GFP-ferroportin assay. Dab,
diaminobutyric acid; Cha, cyclohexylalanine; Nle, norleucine; O, hydrox-
yproline.
a n = 3–6.
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Structure/Function Studies on Hepcidinis sufficient for activity (Figure 4C). This suggestion is further sup-
ported by the data associated with the introduction of a more
polar residue, tyrosine, which causes some loss of activity
(75% ± 22%). The interaction is also stereospecific because
substitution with D-phenylalanine results in a peptide with an
activity of only 29% ± 15% relative to hepcidin. Substitution of
Ile6 with a phenylalanine leads to a loss in activity (64% ± 4%),
suggesting that a bulkier aromatic ring at this position cannot
be accommodated by ferroportin as easily as the branched
isoleucine (Figure 4D). Mutation to a D-isoleucine also results
in a loss of activity (55% ± 2%), implying that there is a stereo-
chemical preference for the interaction.
Because the interaction between hepcidin and ferroportin
appeared to be dominated by hydrophobic interactions, two
additional mutants were synthesized, with Pro5 altered to
a hydroxyproline and the highly conserved Ile8 and Phe9 resi-
dues to a lysine. Neither the mutation of Pro5 to hydroxyproline
or Ile8 to lysine resulted in any substantial loss of hepcidin
activity (Table 1). As stated earlier, we were unable to produce
a correctly folded F9K mutant.Chemistry & Biology 18, 3To examine the role of the disulfide bonds in the interaction
between hepcidin and ferroportin, a series of selenocysteine
analogs of hepcidin were synthesized and tested for their ability
to induce ferroportin internalization and degradation (Figure 5A).
Interestingly, all of the diselenide analogs exhibited an almost
identical dose-response curve to hepcidin (Figure 5B), suggest-
ing that a thiol exchange between hepcidin and ferroportin is not
essential for hepcidin activity. However, reduction/alkylation
assays on native and Sec8 hepcidin revealed that although
[Sec8]hepcidin was more stable to reduction by DTT than native
hepcidin, the peptide could still be reduced (Figure S2). Interest-
ingly, if the reaction time was extended, [Sec8]hepcidin was
found to reoxidize, presumably due to exhaustion of DTT in the
reaction.
Antagonists of hepcidin have the potential to be used as
a treatment for anemia of inflammation, an iron deficiency
disease that results from chronic overproduction of hepcidin.
Therefore, the less-active mutants synthesized in this study
were tested for their ability to act as antagonists of native hepci-
din. None of the hepcidin analogs exhibited antagonistic activity
against the action of hepcidin in the ferroportin-GFP assay when
hepcidin and each analog were coincubated (data not shown).
DISCUSSION
In this study we have characterized the key N-terminal residues
of hepcidin involved in its interaction with ferroportin. Figure 6A
summarizes the structure/activity data known for hepcidin from
natural mutations (Biasiotto, et al., 2003; Jacolot, et al., 2004;
Merryweather-Clarke, et al., 2003; Nemeth, et al., 2006),
previous studies, (Nemeth, et al., 2006; Nemeth, et al., 2004)
and this work. Substitution of His3, Phe4, or Ile6 with alanine
resulted in a substantial loss in the ability of the hepcidin mutants
to trigger the internalization and degradation of ferroportin. More
extensive substitutions at each of these positions revealed that
the interaction between hepcidin and ferroportin is dominated
by hydrophobic interactions because mutation of any of the
identified residues in hepcidin with charged amino acids resulted
in a complete loss of activity. Finally, a change in stereochem-
istry of Phe4 and Ile6 by substitution with the corresponding
D amino acid caused a significant loss of activity. This suggests
that these interactions are also stereospecific.
Figure 6B maps the structure/activity data onto the molecular
surface of hepcidin. It can clearly be seen that His3, Phe4, and
Ile6 form a localized patch at one end of the molecule and that
this patch is flanked by the other N-terminal residues that have
a small to moderate influence on activity. The known natural
hepcidin mutant, G21D, and the synthetic mutant, M21Y, exhibit
comparable activity to native hepcidin (Nemeth, et al., 2006).
Based on the data obtained from this study and truncations of
the N terminus (Nemeth, et al., 2006), this finding is not surprising
because both these residues are located at the opposite end of
the molecule to the activity hot spot. The importance of the
N-terminal residues in the interaction of hepcidin with ferroportin
is further highlighted by a comparison of mammalian hepcidin
sequences. Figure 6C illustrates the fact that the N-terminal
residues important for biological activity are among the most
highly conserved, whereas residues located away from the
activity center, around the b-turn, are less conserved.36–343, March 25, 2011 ª2011 Elsevier Ltd All rights reserved 339
Figure 4. Biological Activity of the Synthetic
Hepcidin Mutants
Relative activities of native hepcidin and the
alanine mutants (A), His3 mutants (B), Phe4
mutants (C), and Ile6 mutants (D). HEK293T cells
stably expressing ferroportin-GFP construct
were treated with peptide (0.3 mM) for 24 hr, and
the intensity of green fluorescence was then
measured by FACS and expressed as
a percentage relative to native hepcidin.
Chemistry & Biology
Structure/Function Studies on HepcidinThe extracellular loop of ferroportin that interacts with hepci-
din has recently been identified from the observation that
Cys326 mutation in this loop results in ferroportin being resistant
to hepcidin binding (De Domenico, et al., 2005; Fernandes, et al.,
2009). It has been proposed that the free thiol of the Cys326
residue forms a disulfide bond with one of the cysteine residues
in hepcidin (Fernandes, et al., 2009). We attempted to test this
hypothesis by synthesizing a series of diselenide bond mutants
of hepcidin. Diselenide bonds are structurally analogous to disul-
fide bonds but are more resistant to reduction (Armishaw, et al.,
2006; Muttenthaler and Alewood, 2008). Therefore, we envis-
aged that if a hepcidin disulfide bond was involved in a disulfide
exchange with ferroportin, replacement of this bond with a dise-
lenide would result in a loss of activity. Diselenide analogs were
designed to test the effects of replacing both individual and
multiple disulfide bonds, and all peptides were shown to be
structurally comparable by NMR secondary shift analysis. This
analysis also confirmed the recently revised disulfide connec-
tivity and three-dimensional structure of hepcidin because the
[C10U,C13U]hepcidin and [C14U,C22U]hepcidin analogs had
identical secondary shifts to native hepcidin (Jordan, et al.,
2009). Activity assays revealed that the activity of all the disele-
nide analogs was comparable to native hepcidin, suggesting
that no disulfide exchange occurs between the hepcidin and
receptor. However, in reduction trials we found that it was340 Chemistry & Biology 18, 336–343, March 25, 2011 ª2011 Elsevier Ltd All rights reservedpossible to reduce [Sec8]hepcidin with
DTT, and therefore, the occurrence of di-
sulfide exchange between hepcidin and
ferroportin cannot be unequivocally
resolved.
None of the hepcidin analogs exhibited
enhanced activity compared with native
hepcidin, a finding that might be due to
one of several reasons. First, the ferro-
portin-GFP degradation assay used is
designed to give maximal degradation
of ferroportin-GFP when incubated with
native hepcidin and, therefore, might
only detect mutants with decreased
activity. Also, the native hepcidin se-
quencemight be optimized for its interac-
tion with ferroportin, which is supported
by the high sequence conservation
across species, and therefore, the exist-
ing interactions are highly efficient. For
example, in the case of Phe4, it appears
that this interaction is simply a hydro-phobic one that is relatively tolerant to size as long as the correct
stereochemistry is maintained. Alternatively, single-point muta-
tions might not be sufficient to enhance activity significantly,
and multi-point mutation analogs might be needed to produce
a more efficacious hepcidin analog. Finally, it is also possible
that there are mutations at these positions that could improve
activity that were not synthesized in this study and that the incor-
poration of unnatural amino acids into the sequence of hepcidin
and variation of noncritical amino acids to introduce additional
contacts might be avenues to explore for the production of
more potent hepcidin analogs.
Hepcidin has an exceptionally high cysteine content relative to
other proteins (Fahey, et al., 1977), with eight of the 25 residues
being cysteine (30%). When eight cysteines are present in
a peptide, there are 105 possible four-disulfide isomers that
can be produced from a random oxidation. Therefore, it is very
surprising that it is possible to fold hepcidin in vitro into the native
isomer, even in the denaturing conditions used in this study. In
a stunning illustration of this robust folding, we observed that
correctly folded [Sec8]hepcidin was formed spontaneously
during the hydrofluoric acid cleavage reaction. Presumably,
there are interactions between residues within the sequence
that drive the correct folding of hepcidin to favor the native
disulfide connectivity. Our results show that the F9K and G20F
mutations disrupted folding, suggesting that these changes to
Figure 5. SelenocystineAnalogsofHepcidin
(A) Schematic representation of native hepcidin
and the selenocystine analogs synthesized in this
study. The peptide backbone is represented by
the black line, disulfides as the white ball and
sticks, and diselenides as the gray ball and sticks.
Each disulfide/diselenide is numbered based on
its position in the sequence.
(B) Dose-response curve for hepcidin (filled dia-
monds), [U7C,U23C]hepcidin (filled squares),
[C10U,C13U]hepcidin (filled triangles), [C11U,
C19U]hepcidin (filled circles), [C14U, C22U]hepci-
din (open squares), [Sec4]hepcidin (open trian-
gles), and [Sec8]hepcidin (open circles).
HEK293T cells stably expressing ferroportin-GFP
construct were treated with varying concentra-
tions of peptide for 24 hr, and the intensity of green
fluorescence was then measured by FACS.
See also Figure S2.
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Structure/Function Studies on Hepcidinthe hepcidin sequence introduce interactions unfavorable to
formation of the native disulfide isomer.
It is interesting to consider what role the framework of hep-
cidin plays in its biological function, considering that many of
the key residues important for biological activity are localized
within the flexible N terminus. It has been shown that the
N terminus alone is not sufficient for activity (Nemeth, et al.,
2006), which implies a role for other residues within the frame-
work. In addition to the conserved cysteines, which provide
structural stability to the molecule and might form an inter-
molecular disulfide with ferroportin, there are a number of resi-
dues within the hepcidin sequence that are conserved across
species (Figure 6C), and it is possible that these could be
important for either the interaction of hepcidin with ferroportin
or might modulate other processes in the internalization
mechanism.Chemistry & Biology 18, 336–343, March 25, 2011SIGNIFICANCE
Hepcidin is themajor peptide hormone
in the body regulating iron levels.
There are a number of diseases
associated with the dysregulation of
hepcidin levels in humans, including
hemochromatosis (iron overload) and
anemia (low iron levels). This study
represents a first step toward defining
the hepcidin pharmacophore at the
ferroportin-binding site, and the data
generated could be crucial in the
development of agonists or antago-
nists for the treatment of iron-related
disorders. We have identified the key
positions within the N terminus of
hepcidin for its ability to trigger inter-
nalization and degradation of ferropor-
tin and have elucidated the chemical
and structural requirements at each
of these positions. Our findings,
combined with literature data, haveallowed us to propose a mechanistic model for the hepci-
din/ferroportin interaction that we can interrogate in future
studies and will be invaluable in the drug development
process.EXPERIMENTAL PROCEDURES
Peptide Synthesis
All peptides were assembled on 2-Cl-2-trityl resin (Novabiochem) by solid-
phase peptide synthesis on a Liberty Microwave Peptide Synthesizer using
the in situ neutralization/HBTU protocol and Fmoc chemistry (Schno¨lzer,
et al., 1992). Cleavage of the peptides from the resin was achieved using
TFA with triisopropylsilane and water as scavengers (9:0.5:0.5 [v/v] TFA:triiso-
propylsilane:water) at 22C for 2 hr. The selenocysteine analogs of hepcidin
were synthesized with the in situ neutralization/HBTU protocol and Boc
chemistry using Boc-Sec(MeBzl)-OH at sites where selenocysteine was
replacing cysteine. These peptides were cleaved using HF with p-cresol andª2011 Elsevier Ltd All rights reserved 341
Figure 6. Summary of Structure/Activity
Relationships of Hepcidin
(A) The sequence of hepcidin showing the effect
on activity of mutations from this study, naturally
occurring mutations and truncation of the
N-terminal residues (indicated by the X symbol)
(Nemeth, et al., 2006). The colors indicate the
percent loss in activity relative to hepcidin as
follows: green <10% loss in activity, yellow 10%–
20% loss, orange 20%–50% loss, and red >50%
loss. Mutations shown in magenta are peptides
that did not fold.
(B) A surface representation of hepcidin with the
surface color coded using the same scheme as
(A). The activity data presented are for the alanine
mutants plus the known natural mutations. It can
be seen that residues His3, Phe4, and Ile6 form
a localized patch on the surface of the molecule.
The conserved cysteines are colored yellow.
(C) A sequence logo representation (Schneider
and Stephens, 1990) of hepcidin, colored using
the scheme from (A). The activity data presented
are for the alanine mutants together with the
known natural mutations and the C-terminal
truncation data (Nemeth, et al., 2006). The relative
heights of the amino acid symbols at each position
represent the degree of sequence conservation at
each of these positions. As expected, the residues
toward the N-terminal region of the peptide that
are important for the interaction of hepcidin are
the most highly conserved, whereas those around
the b-turn show lower sequence conservation.
Chemistry & Biology
Structure/Function Studies on Hepcidinp-thiocresol as scavengers (9:0.5:0.5 [v/v)]HF:p-cresol:p-thiocresol). The
reaction was allowed to proceed at 5C–0C for 1.5 hr. The HF was then
removed under vacuum and the peptide precipitated with ether, filtered,
dissolved in 50% acetonitrile containing 0.05% TFA, and lyophilized. After
cleavage, the peptide was precipitated with ether, filtered, and then dissolved
in 50% acetonitrile containing 0.05% TFA and lyophilized. Crude peptides
were purified by RP-HPLC on a C18 column using a gradient of 0%–80%
B (A, H2O/0.05% TFA; B, 90% CH3CN/10% H2O/0.045% TFA) in 80 min.
Analytical RP-HPLC and ES-MS confirmed the purity and molecular mass of
the synthesized peptides.
The reduced peptides were oxidized by incubating in 0.1 M sodium phos-
phate buffer containing 4 M guanidine, 2 mM EDTA, 3 mM cysteine, and
0.15 mM cystine (pH 7.8) for approximately 18 hr at room temperature. The
reaction mixture was purified by RP-HPLC to yield the cyclic/oxidized
peptides. Analytical RP-HPLC and ES-MS confirmed the purity of the final
products. All hepcidin analogs were stored as lyophilized solids at 20C.
NMR Studies
Structural data for the hepcidin analogs were obtained using NMR spectros-
copy for samples dissolved in 90% H2O and 10% D2O at a pH of approxi-
mately 4. A Bruker Avance 600 MHz NMR spectrometer was used to acquire
spectra, including 1H, TOCSY, and NOESY data, as described previously
(Clark, et al., 2006a, 2006b) and processed using Topspin (Bruker). All spectra
were recorded at 298 K. Processed spectra were analyzed and assigned
within the program Sparky (Goddard and Kneller, 2008).
Flow Cytometry
ECR293-Fpn, a cell line stably transfected with the mouse ferroportin-GFP
construct under the control of ponasterone-inducible promoter, was prepared342 Chemistry & Biology 18, 336–343, March 25, 2011 ª2011 Elsevieand maintained as described previously (Nemeth, et al., 2004). Briefly, cells
expressing Fpn-GFP were treated with peptides (0.3 mM) for 24 hr. Peptide
concentrations were determined by measurement of absorbance at 214 nm
and using a calculated extinction coefficient based on the peptide sequence
(Moffatt, et al., 2000). Cells not induced with ponasterone to express Fpn-
GFP were used to establish a gate to exclude background fluorescence, and
cells induced with ponasterone, but not treated with peptides, were used as
the positive control. After treatment with hepcidin or its mutated analogs
(n = 3–6), the cells lost fluorescence in proportion to the activity of eachpeptide.
The resultswere expressedas a fraction of the activity of hepcidin, according to
the formula: 1 [(Fx Fhep25)/(Funtreated Fhep25)], where F was the mean frac-
tion of cells within the green fluorescence gate, and x was the peptide.
Antagonist Competition of Hepcidin
ECR293-Fpn, a cell line stably transfected with the mouse ferroportin-GFP
construct under the control of ponasterone-inducible promoter, was prepared
and maintained as described previously (Nemeth, et al., 2004). Briefly, cells
expressing Fpn-GFP were treated with Hep25 (0.717 mM) and with mutant
(3.3–3.6 mM) simultaneously for 24 hr.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and can be found with this
article online at doi:10.1016/j.chembiol.2010.12.009.
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